Abstract: The invention relates to a compound characterized by general formula (100), wherein R1 and R6 are H or F, R2, R3, R4 and R5 can be any substituent, R7, R8, RN1, RN2, RN3 and RN4 are a hydrocarbon moiety, one of R9 and R10 is hydrogen and the other one is hydrogen or a saturated carbon atom connected to any substituent, and its use in staining and live cell fluorescence imaging.

Abstract: The invention relates to a compound characterized by general formula (100), wherein R1 and R6 are H or F, R2, R3, R4 and R5 can be any substituent, R7, R8, RN1, RN2, RN3 and RN4 are a hydrocarbon moiety, one of R9 and R10 is hydrogen and the other one is hydrogen or a saturated carbon atom connected to any substituent, and its use in staining and live cell fluorescence imaging.

Abstract: The invention relates to the in vitro and in cellulo detection of the cofactors nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). Provided is a sensor molecule for fluorescence- or luminescence-based detection of a nicotinamide adenine dinucleotide analyte, in particular for detecting the concentrations of NAD+, NADP+ and/or the ratios of the concentrations of NAD+/NADH and NADP+/NADPH, the sensor comprising (i) a binding protein (BP) for the nicotinamide adenine dinucleotide analyte, the BP being derived from sepiapterin reductase (SPR; EC 1.1.1.153) (ii) an SPR ligand (SPR-L) capable of intramolecular binding to said BP in the presence of the oxidized form of said analyte; and (iii) at least one fluorophore.

Abstract: The invention relates to the in vitro and in cellulo detection of the cofactors nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). Provided is a sensor molecule for fluorescence or luminescence-based detection of a nicotinamide adenine dinucleotide analyte, in particular for detecting the concentrations of NAD+, NADP? and/or the ratios of the concentrations of NAD?/NAD H and NADP?/NADPH, the sensor comprising (i) a binding protein (BP) for the nicotinamide adenine dinucleotide analyte, the BP being derived from sepiapterin reductase (SPR; EC 1.1.1.153) (ii) a SPR ligand (SPR-L) capable of intramolecular binding to said BP in the presence of the oxidized form of said analyte; and (iii) at least one fluorophore.

Abstract: The present invention refers to a double-stranded siRNA molecule comprising a sense Strand and an antisense Strand which is essentially complementary to the sense Strand, each of the sense and the antisense Strands comprising at least 17 nucleotides (nt), the siRNA further comprising at least one overhang at the 5? and/or 3? end, wherein the overhang residue or overhang residues are chemically modified and selected independently from each other from the group consisting of: (a) 2?-deoxy modified nucleotides; (b) 2?-methoxy modified nucleotides; (c) two nucleosides linked by a 3? to 5? or 2? to 5? formacetal linkage; (d) nucleotides modified at the 2?-position by a —O—CH2—O—(CH2)2—OH group; and (e) nucleotides comprising in the 3?-position a —CH2—O—(CH2)7—CH3 group.

Abstract: The present invention refers to a double-stranded siRNA molecule comprising a sense Strand and an antisense Strand which is essentially complementary to the sense Strand, each of the sense and the antisense Strands comprising at least 17 nucleotides (nt), the siRNA further comprising at least one overhang at the 5? and/or 3? end, wherein the overhang residue or overhang residues are chemically modified and selected independently from each other from the group consisting of: (a) 2?-deoxy modified nucleotides; (b) 2?-methoxy modified nucleotides; (c) two nucleosides linked by a 3? to 5? or 2? to 5? formacetal linkage; (d) nucleotides modified at the 2?-position by a -0-CH2—O—(CH2)2—OH group; and (e) nucleotides comprising in the 3?-position a —CH2—O—(CH2)7—CH3 group.